These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23732307)

  • 41. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons.
    Tani N; Kawai N; Ikematsu H; Bando T; Iwaki N; Takasaki Y; Shindo S; Chong Y; Kashiwagi S
    J Infect Chemother; 2022 Jul; 28(7):890-895. PubMed ID: 35317975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.
    Lancet; 1998 Dec; 352(9144):1877-81. PubMed ID: 9863784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate.
    Kawaguchi T; Arinaga-Hino T; Shimizu M; Tanikawa K; Tokushige T; Hirai S; Nagamatsu H; Tateishi H; Takata A; Ide T; Torimura T
    Intern Med; 2019 Sep; 58(17):2501-2505. PubMed ID: 31118398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.
    Kaiser L; Keene ON; Hammond JM; Elliott M; Hayden FG
    Arch Intern Med; 2000 Nov; 160(21):3234-40. PubMed ID: 11088083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial.
    Ikematsu H; Baba T; Saito MM; Kinoshita M; Miyazawa S; Hata A; Nakano S; Kitanishi Y; Hayden FG
    Influenza Other Respir Viruses; 2024 May; 18(5):e13302. PubMed ID: 38706384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.
    Lalezari J; Campion K; Keene O; Silagy C
    Arch Intern Med; 2001 Jan; 161(2):212-7. PubMed ID: 11176734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications.
    Gravenstein S; Johnston SL; Loeschel E; Webster A
    Drug Saf; 2001; 24(15):1113-25. PubMed ID: 11772145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Trujillo A; Barnes J; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2015 Jun; 15(6):654-62. PubMed ID: 25788164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
    Webster A; Boyce M; Edmundson S; Miller I
    Clin Pharmacokinet; 1999; 36 Suppl 1():51-8. PubMed ID: 10429840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Niwa S; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.
    Welliver R; Monto AS; Carewicz O; Schatteman E; Hassman M; Hedrick J; Jackson HC; Huson L; Ward P; Oxford JS;
    JAMA; 2001 Feb; 285(6):748-54. PubMed ID: 11176912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population.
    Ambrozaitis A; Gravenstein S; van Essen GA; Rubinstein E; Balciuniene L; Stikleryte A; Crawford C; Elliott M; Shult P
    J Am Med Dir Assoc; 2005; 6(6):367-74. PubMed ID: 16286057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
    Jefferson TO; Demicheli V; Di Pietrantonj C; Jones M; Rivetti D
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001265. PubMed ID: 16855962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
    Cooper NJ; Sutton AJ; Abrams KR; Wailoo A; Turner D; Nicholson KG
    BMJ; 2003 Jun; 326(7401):1235. PubMed ID: 12791735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
    Hirotsu N; Saisho Y; Hasegawa T
    Influenza Other Respir Viruses; 2019 Mar; 13(2):123-132. PubMed ID: 29989680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Zanamivir: an update of its use in influenza.
    Cheer SM; Wagstaff AJ
    Drugs; 2002; 62(1):71-106. PubMed ID: 11790157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.